Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRM7 antisense RNA 3 (GRM7-AS3), also known as LINC01406, is a long non-coding RNA gene transcribed from the opposite strand of the GRM7 locus on chromosome 3[2][3][4]. It does not code for protein but is expressed in multiple tissues, including brain, heart, and liver. GRM7-AS3 has been implicated in gene regulatory processes, possibly affecting the expression of GRM7 or interacting with diverse RNAs/proteins[2]. Genome-wide association studies have linked genetic variation in GRM7-AS3 to depressive symptoms in older adults, and indirect links exist to neuropsychiatric disease, although the direct molecular functions and mechanisms at the disease level are still under research[4]. Currently, GRM7-AS3 is not considered a classic receptor, enzyme, or drug target, but it may be relevant as a susceptibility gene or biomarker in neuropsychiatric research[2][3][4].
N/A — not a druggable protein or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRM7 antisense RNA 3 (non-protein coding) (GRM7-AS3).